Adagene Inc. Files 2024 Annual Report
Ticker: ADAG · Form: 20-F · Filed: 2025-03-24T00:00:00.000Z
Sentiment: neutral
Topics: annual-report, 20-F, pharmaceuticals
TL;DR
Adagene dropped its 2024 20-F. Check financials.
AI Summary
Adagene Inc. filed its annual report on Form 20-F for the fiscal year ending December 31, 2024. The company, incorporated in E9 and headquartered in Suzhou Industrial Park, Jiangsu, operates in the Pharmaceutical Preparations sector. The filing details its financial performance and business operations for the reporting period.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Adagene Inc.'s financial health and strategic direction for the past fiscal year, crucial for investment decisions.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Adagene faces inherent risks related to drug development, regulatory approvals, and market competition, which are detailed in its 20-F filing.
Key Numbers
- 20241231 — Fiscal Year End (Indicates the period covered by the financial statements.)
- 20250324 — Filing Date (Date the 20-F was submitted to the SEC.)
Key Players & Entities
- Adagene Inc. (company) — Filer of the 20-F
- 20241231 (date) — Fiscal year end
- 20250324 (date) — Filing date
- 001-39997 (dollar_amount) — SEC file number
- Suzhou Industrial Park (company) — Business address location
FAQ
What is Adagene Inc.'s primary business sector?
Adagene Inc. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code [2834].
When did Adagene Inc. file its 20-F report?
Adagene Inc. filed its 20-F report on March 24, 2025.
What is the fiscal year end for Adagene Inc. in this filing?
The fiscal year end for Adagene Inc. in this filing is December 31, 2024.
Where is Adagene Inc. located?
Adagene Inc.'s business and mailing address is located at 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park, Jiangsu.
What is the SEC file number for Adagene Inc.'s filing?
The SEC file number for Adagene Inc.'s filing is 001-39997.
From the Filing
0001410578-25-000419.txt : 20250324 0001410578-25-000419.hdr.sgml : 20250324 20250324080535 ACCESSION NUMBER: 0001410578-25-000419 CONFORMED SUBMISSION TYPE: 20-F PUBLIC DOCUMENT COUNT: 127 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250324 DATE AS OF CHANGE: 20250324 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Adagene Inc. CENTRAL INDEX KEY: 0001818838 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 20-F SEC ACT: 1934 Act SEC FILE NUMBER: 001-39997 FILM NUMBER: 25762258 BUSINESS ADDRESS: STREET 1: 4F, BUILDING C14, NO. 218, XINGHU STREET STREET 2: SUZHOU INDUSTRIAL PARK CITY: JIANGSU STATE: F4 ZIP: 00000 BUSINESS PHONE: 86-512-87773632 MAIL ADDRESS: STREET 1: 4F, BUILDING C14, NO. 218, XINGHU STREET STREET 2: SUZHOU INDUSTRIAL PARK CITY: JIANGSU STATE: F4 ZIP: 00000 20-F 1 adag-20241231x20f.htm 20-F Adagene Inc._December 31, 2024 http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#UsefulLifeTermOfLeaseMember http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#SubsidiaryOfCommonParentMember http://fasb.org/us-gaap/2024#SubsidiaryOfCommonParentMember http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#SubsidiaryOfCommonParentMember http://fasb.org/us-gaap/2024#SubsidiaryOfCommonParentMember http://fasb.org/us-gaap/2024#MajorityShareholderMember http://fasb.org/us-gaap/2024#MajorityShareholderMember http://fasb.org/us-gaap/2024#RelatedPartyMember http://fasb.org/us-gaap/2024#RelatedPartyMember 55145839 P3Y P3Y P5Y 58886944 0001818838 FY 2024 false 4F, Building C14, No. 218 Xinghu Street, Suzhou Industrial Park Suzhou 215123 CN true 0.50 0001818838 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001818838 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001818838 dei:AdrMember 2022-01-01 2022-12-31 0001818838 adag:ShareRepurchaseProgramOf2022Member us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001818838 adag:ShareRepurchaseProgramOf2022Member us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001818838 adag:ShareRepurchaseProgramOf2022Member dei:AdrMember 2022-01-01 2022-12-31 0001818838 adag:ShareRepurchaseProgramOf2021Member us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001818838 adag:ShareRepurchaseProgramOf2021Member dei:AdrMember 2022-01-01 2022-12-31 0001818838 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-12-31 0001818838 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-12-31 0001818838 dei:AdrMember 2024-12-31 0001818838 us-gaap:CommonStockMember 2023-12-31 0001818838 dei:AdrMember 2023-12-31 0001818838 adag:ShareRepurchaseProgramOf2022Member 2022-06-29 2022-06-29 0001818838 adag:ShareRepurchaseProgramOf2021Member 2021-07-07 2021-07-07 0001818838 dei:AdrMember adag:AtmOfferingMember 2024-01-01 2024-12-31 0001818838 adag:AtmOfferingMember 2024-01-01 2024-12-31 0001818838 us-gaap:RetainedEarningsMember 2024-12-31 0001818838 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001818838 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001818838 us-gaap:TreasuryStockCommonMember 2023-12-31 0001818838 us-gaap:RetainedEarningsMember 2023-12-31 0001818838 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001818838 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001818838 us-gaap:TreasuryStockCommonMember 2022-12-31 0001818838 us-gaap:RetainedEarningsMember 2022-12-31 0001818838 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001818838 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001818838 us-gaap:TreasuryStockCommonMember 2021-12-31 0001818838 us-gaap:RetainedEarningsMember 2021-12-31 0001818838 us-gaap:Addi